Formycon's Ranibizumab biosimilar, FYB201/Ravegza, receives Saudi marketing authorization and plans to expand in the MENA region in 2024.

Formycon AG's FYB201/Ranibizumab, a biosimilar to Lucentis®, gains momentum with Saudi Food & Drug Authority's marketing authorization. Following a successful market launch in Jordan and winning a government tender in Saudi Arabia, the launch of FYB201/Ravegza® is planned in the second quarter of 2024. Further launches are planned throughout 2024 to improve access to ophthalmic treatments in the MENA region.

March 11, 2024
3 Articles